Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3^rd June 2024, 9am CET

Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR). 

The parties will initially use Partex’ technologies, under its Asset Exchange platform, to identify novel indications with associated clinical paths and markets for EDDC’s portfolio assets. The parties intend to broaden this partnership to combine AI technology, scientific expertise and wet lab validations to accelerate the progress of new drug discovery programs. Partex will bring its industry validated, AI-powered in-silico platform for novel target identification, de novo molecule generation, as well as structure-activity relationship (SAR) and optimization across small and large molecules. The partners will also leverage Partex’s      proprietary knowledge graph, small molecule screening library and real world data. EDDC will bring substantial expertise and experience in a full range of drug discovery and development capabilities from initial discovery through clinical proof-of-concept.

“At Partex, we stand at the cusp of Artificial Intelligence and translational medicine to transform the pace of new drug discovery. Our collaboration with EDDC will allow us to integrate lab driven experimental data from state-of-the-art facilities to train, optimize and validate AI models and rapidly prove new hypothesis.” said Dr. Gunjan Bhardwaj, Founder of Partex. “Together with EDDC we envision bringing forward promising therapeutic candidates for unmet indications.”

“EDDC’s mission is to translate innovative scientific discoveries into great medicines. Partnering with Partex allows us to leverage cutting-edge AI technology alongside our comprehensive drug discovery and development expertise,” said Prof Damian O’Connell, Chief Executive Officer of EDDC. “Together, we are poised to accelerate the journey from groundbreaking research to life-changing treatments, addressing diseases with critical unmet needs.”

For media inquiries and further information, please contact:
Partex
Nidhi Duhan
Business Operations Manager
info@partex.io

About Partex:

With the power of AI at its core, the Partex Group delivers faster, lower-cost healthcare innovations, validated by wet-lab and real-world evidence. Our pioneering digital platform enables smarter decision-making throughout the entire value chain. Partex’s pioneering digital life-science platform leverages the largest knowledge graph in the industry to impact the full pharma and healthcare value chain. Our agile teams use a flexible and scalable data exchange and insight generation approach to enable maximally informed decision-making. To further solidify the translation of AI-generated predictions into tangible outcomes, Partex’s Contract Research Organization (CRO), Assay.Works, can conduct wet lab validation for selected indications upon client’s request. This critical step underscores the commitment to delivering safe and efficacious therapies to patients. We deliver value to patients, clients, and investors through faster, lower-cost healthcare innovations with an increased probability of success.

With a global presence that extends from Asia-Pacific to the Americas, with offices currently in India, Germany, Switzerland, and the USA, Partex’s vision is to transform the Life Science Industry by solving the inefficiency problem in drug discovery & development using Big Data & Artificial Intelligence.

Partex group companies: https://www.partex.io/ https://www.innoplexus.com/ https://www.cureteq.com/ www.amrit.ai https://www.assay.works/ https://perpetualblock.io/

For more information, visit https://www.partex.io/ and follow us on LinkedIn, Twitter and Instagram.

About EDDC:

The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions.

For more information about EDDC, please visit http://www.eddc.sg/

Featured News